Changes in Intraocular Pressure After Intravitreal Injection

NCT07826286 | Not Yet Recruiting

• 1 other identifier: Post-Intravitreal IOP Changes
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP). The purpose of this prospective observational study is to evaluate the immediate and early changes in intraocular pressure following intravitreal anti-VEGF injections and to determine how rapidly pressure recovers toward baseline levels. Adult participants scheduled to receive routine intravitreal anti-VEGF therapy for established clinical indications, such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion, will be enrolled. Intraocular pressure will be measured using an Icare rebound tonometer with single-use disposable probes before injection (baseline) and at 1 minute, 5 minutes, and 20 minutes post-injection. The study will also analyze whether factors such as refractive error, the number of prior injections, or the type of anti-VEGF drug administered affect the severity of post-injection pressure spikes and subsequent recovery.

Conditions

Diabetic Macular Edema; Neovascular Age-Related Macular Degeneration; Retinal Vein Occlusion; Ocular Hypertension

Keywords

Intraocular Pressure; Intravitreal Injections; Anti-VEGF; Icare Tonometry; Rebound Tonometry; Bevacizumab; Ranibizumab

Outcome Measures

Primary Outcomes (3)

• Change from Baseline in Intraocular Pressure at 1 Minute

  Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to assess the acute post-injection pressure spike compared to baseline.

  Baseline and 1 minute post-injection

• Change from Baseline in Intraocular Pressure at 5 Minutes

  Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to evaluate early post-injection pressure trends.

  Baseline and 5 minutes post-injection

• Change from Baseline in Intraocular Pressure at 20 Minutes

  Intraocular pressure will be measured in mmHg using an Icare rebound tonometer to assess the rate and extent of pressure recovery toward pre-injection baseline levels.

  Baseline and 20 minutes post-injection

Study Arms (1)

Intravitreal Anti-VEGF Injection Cohort

Patients aged 18 years and older scheduled to receive an intravitreal anti-VEGF injection for established clinical indications, including diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion. Participants undergo baseline ophthalmic evaluation followed by intraocular pressure (IOP) monitoring at 1 minute, 5 minutes, and 20 minutes post-injection using an Icare rebound tonometer.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients attending the Ophthalmology Department at El Mabara Hospital in Assiut, Egypt, who are scheduled to receive routine intravitreal anti-VEGF injections for vitreoretinal conditions such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion.

You may qualify if:

• Age 18 years or older.
• Scheduled to receive an intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for an established clinical indication (e.g., diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion).
• Provision of written informed consent prior to enrollment.

You may not qualify if:

• Known history of glaucoma or ocular hypertension.
• History of previous glaucoma surgery.
• Corneal diseases or ocular conditions that significantly interfere with accurate intraocular pressure measurement.
• Inability to cooperate adequately during intraocular pressure measurement.
• Refusal to participate or failure to provide informed consent.
• Development of marked intraocular pressure elevation immediately after injection (IOP ≥ 40 mmHg) requiring anterior chamber paracentesis.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Retinal Vein Occlusion; Ocular Hypertension

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Venous Thrombosis; Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Ophthalmology

Study Record Dates

• First Submitted: September 13, 2026
• First Posted: September 17, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: September 17, 2026

Record last verified: 2026-09